NCT01093781View on ClinicalTrials.gov

Aliskiren in Patients With Idiopathic Membranous Nephropathy

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Idiopathic Membranous Nephropathy
Interventions
DRUG

Aliskiren

Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01093781 - Aliskiren in Patients With Idiopathic Membranous Nephropathy | Biotech Hunter | Biotech Hunter